InvestorsHub Logo
Followers 52
Posts 9087
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Friday, 05/19/2023 9:08:00 AM

Friday, May 19, 2023 9:08:00 AM

Post# of 13457
Moderna,Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), presented at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.

More than 280 doses of mRNA-3927 were administered. Five patients have more than a year of dosing


https://investors.modernatx.com/news/news-details/2023/Phase-12-Interim-Data-on-Modernas-mRNA-3927-an-Investigational-mRNA-Therapy-for-Propionic-Acidemia-PA-Presented-at-the-2023-ASGCT-Annual-Meeting/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News